Inspire Medical Systems, Inc.
Inspire Medical Systems Expects to Release Valuation Allowance, Boosting EPS by $3.00 to $3.30
Summary
On November 6, 2025, Inspire Medical Systems, Inc. announced its expectation to release a significant portion of the valuation allowance on its U.S. deferred tax assets during the fourth quarter of fiscal 2025. This action is estimated to result in an income tax benefit in the range of $90 million to $100 million, which is expected to increase diluted earnings per share by approximately $3.00 to $3.30 for the year.
Profitelligence Alerts
Get alerts for INSP
Be first to know when Inspire Medical Systems, Inc. files with the SEC.
Filing Categories
Advertisement
About Inspire Medical Systems, Inc.
Inspire Medical Systems, Inc. is a pioneering company focused on developing and commercializing innovative medical technology designed to treat obstructive sleep apnea (OSA). The company's flagship product, the Inspire therapy, is an implantable neurostimulation device that provides a unique and effective solution for patients who are unable to utilize traditional continuous positive airway pressure (CPAP) devices. Inspire Medical Systems significantly impacts the healthcare sector by offering a less invasive, patient-friendly alternative to surgical treatments for OSA, improving quality of life for those affected by sleep disorders. Headquartered in Minnesota, Inspire Medical Systems continues to expand its presence within the medical device market, collaborating closely with hospitals and medical professionals to enhance sleep health management globally. This company's contributions underscore a growing focus on personalized and technologically advanced approaches to medical challenges, marking its importance in the evolving landscape of healthcare solutions.
Official SEC Documents
Advertisement